Für Forscher

Die Forschung von heute führt zu den Durchbrüchen von morgen.

Tragen Sie sich in unsere Mailingliste ein, um Neuigkeiten und Finanzierungsmöglichkeiten von AFTD Research zu erhalten
Holloway Logo_Final_4-2022_Poppins-Lora-fonts (1) (002)

Holloway-Gipfel

In 2021, AFTD Board member Kristin Holloway generously established the Holloway Family Fund at AFTD, making the Holloway Summit series possible. Each year, the Summit brings together innovative thought-leaders to focus on a different topic in FTD research. Attendees span academic and industry scientists, non-profit and government funders, experts from related fields, and people with lived experience with FTD.

2023: Biomarkers for FTD

2023 Holloway Summit - Attendees

November 29-December 1 | Miami Beach, FL

Chairs: Danielle Graham, PhD (Biogen), Stacie Weninger, PhD (F-Prime Biomedical Research Initiative), Henrik Zetterberg, PhD (University of Gothenburg)

AFTD Leadership: Penny Dacks, PhD (Senior Director of Scientific Initiatives), Debra Niehoff, PhD (Director of Grants and Research), Amanda Gleixner, PhD (Research Project Manager)

Program: Klicke hier, um anzusehen

Topics:

  • Data and biosample resources to accelerate biomarker development
  • Current and emergent biomarkers for FTD
  • Biomarker approaches to identify which patients have which causes of FTD
  • Biomarker approaches to improve access to early and accurate diagnosis
  • Biomarker approaches to enable clinical trials for potential treatments

More information on the meeting can be found here: Second Holloway Summit Showcases Intense Search for FTD Biomarkers | ALZFORUM.

2022: Digital Assessment Tools for FTD

Holloway Summit Cover

May 18 - 20 |  Miami, FL

The phrase “digital assessment tools” refers to emerging technologies that allow researchers to use smartphones, wearable trackers, or other devices to remotely measure aspects of a person's health, such as diseases symptoms and function.

Chairs: Naomi Nevler, MD (University of Pennsylvania) und Jonathan Rohrer, MD (University College London and the Genetic Frontotemporal Dementia Initiative)

AFTD Leadership: Penny Dacks, PhD (Senior Director of Scientific Initiatives) und Debra Niehoff, PhD (Director of Grants and Research)

Topics:

  • Development of tools to remotely measure the diverse potential symptoms of FTD.
  • How digital assessment tools can reduce travel burden to expand access to clinical trial participation, diagnosis, and care.
  • Roadmap to successful development of digital assessment tools.
  • Overcoming challenges with digital assessment tools development.

More information on the meeting can be found here: Digital Biomarkers of FTD: How to Move from Tech Tinkering to Trials? | ALZFORUM